Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

Typically poor outcomes for patients with MSI-H/dMMR mCRC are starting to change. Do you know how to incorporate new treatments into your practice?

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Recent immunotherapy approvals have changed the treatment paradigm for first and subsequent lines of treatment for patients with microsatellite-high or mismatch repair deficient metastatic colorectal cancer. Join us as we deep dive into recent and newly emergent data to better understand how to bring these advances into the clinic.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Edward Chu, MD
    Director, Albert Einstein Cancer Center
    Albert Einstein College of Medicine
    Bronx, NY
    No relationships reported 

    Michael J. Overman, MD
    MD Anderson Cancer Center
    Houston, TX
    Consulting Fees:AbbVie, Agilvax, Arcotech Biopharma, Janssen Research & Development, Merck Sharp & Dohme Corp., Pfizer Inc., Takeda Pharmaceutical  

    Reviewers/Content Planners/Authors:

    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Nick Lombardi has disclosed ownership interest: Vertex Pharmaceuticals.
    • Tricia O’Leary has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discuss the importance of molecular testing to identify patients with microsatellite instability-high colorectal cancer.
    • Develop optimal treatment plans, utilizing newly approved immunotherapy, to improve outcomes in patients with MSI-H CRC.
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, oncology nurse practitioners and physician assistants, oncology nurses, and oncology pharmacists with a secondary audience of gastroenterologists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    ReachMD Healthcare Image

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free